MRKR
Marker Therapeutics, Inc.
Next earnings Aug 12, 2026 · consensus $-0.21 EPS, $696K rev
Last earnings -1.5% on 2026-03-19
$1.32
▲ +0.38%$1.32▼ -7.39%
over 1Y
L $0.85EODHDH $2.19
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+0.4%
1W-4.0%
1M-9.3%
3M+1.2%
YTD-14.6%
1Y-7.4%
Avoid
Conviction
Horizon
Medium (3–12mo)
Street · 9 analysts
Buy
Conservative balance sheet (liabilities/equity 0.14x); but revenue fell -46.2% YoY.
Revenue (FY2025) $3.55M · FY2025
Marker Therapeutics, Inc. shows $3.55M in FY2025 revenue (-46.2% YoY), a -343.0% net margin, and -72.4% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $1.24M | $3.51M | $3.31M | $6.59M | $3.55M |
| Gross profit | — | — | — | — | — |
| Operating income | -$39.5M | -$19.8M | -$14.6M | -$11.1M | -$12.9M |
| Net income | -$41.9M | -$29.9M | -$8.24M | -$10.7M | -$12.2M |
| Diluted EPS | -$5.47 | -$3.58 | -$0.94 | -$1.19 | -$0.79 |
| Net margin | -3372.7% | -851.9% | -248.8% | -162.8% | -343.0% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$5.93M
EV / EBITDA—
EV / Sales1.7
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-55.5%
FCF yield-56.5%
Quality & risk
ROIC (est.)-60.4%
Free cash flow-$12.4M
Total debt$67.9K
Net cash$16.0M
Altman Z-Score-28.91 distress
Piotroski F-Score2/7
Capital returns
Buyback yield0.3%
Dividend yield (est.)—
Shareholder yield0.3%
Shares Δ YoY+55.7%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
Recent filings
all on EDGAR ↗10-QPeriod ending 2026-03-312026-05-15open ↗8-KPeriod ending 2026-05-012026-05-04open ↗DEFA14AFiling2026-03-20open ↗ARSPeriod ending 2025-12-312026-03-20open ↗DEF 14APeriod ending 2026-05-012026-03-20open ↗8-KPeriod ending 2026-03-182026-03-19open ↗10-KPeriod ending 2025-12-312026-03-18open ↗PRE 14APeriod ending 2026-05-012026-03-10open ↗8-KPeriod ending 2026-02-092026-02-09open ↗4Period ending 2025-11-172025-11-19open ↗4Period ending 2025-11-172025-11-19open ↗4Period ending 2025-11-172025-11-19open ↗
Frequently asked
- Is Marker Therapeutics, Inc. (MRKR) a buy?
- MRKR currently carries a Avoid rating with 4/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.14x); but revenue fell -46.2% YoY.
- What is Marker Therapeutics, Inc.'s quality score?
- MRKR scores 39.23529411764706/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001094038, latest 10-Q filed 2026-05-15) · EODHD · as of 6/26/2026, 8:18:53 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.